Evidence map›Paper›PMID 39659794›Full record

ArticleFrontiers in oncology2024

Assessment of

Hui Liang, Yao Liu, Suyue Yin, Mengyu Jiang, Qiuyan Dou, Hanhan Wang, Jie Liu, Yibo Chen, Pei Liu, Jing Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hui Liang *Department of Cervical Disease, Xuzhou Maternity and Child Health Hospital, Jiangsu, China.
Yao Liu *Department of Gynecology, Yueyang Central Hospital, Hunan, China.
Suyue Yin *Department of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing, China.
Mengyu JiangDepartment of Cervical Disease, Xuzhou Maternity and Child Health Hospital, Jiangsu, China.
Qiuyan DouDepartment of Cervical Disease, Xuzhou Maternity and Child Health Hospital, Jiangsu, China.
Hanhan WangDepartment of Cervical Disease, Xuzhou Maternity and Child Health Hospital, Jiangsu, China.
Jie LiuDepartment of Clinical Laboratory, Xuzhou Maternity and Child Health Hospital, Jiangsu, China.
Yibo ChenDepartment of Gynecology, Changsha Women and Child Health Care Hospital affiliated to Hunan Normal University, Hunan, China.
Pei LiuDepartment of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing, China.
Jing WangDepartment of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing, China.
Yishan WangDepartment of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing, China.
Zhe WuDepartment of Gynecology, Yueyang Central Hospital, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate the clinical utility of Methods: We enrolled women who underwent opportunistic screening at Cervical Disease outpatient clinics of Xuzhou Maternity and Child Health Hospital, and Yueyang Central Hospital from December 2022 to May 2024. The effectiveness of CISCER and cytology tests in triaging hrHPV+ patients was analyzed. Results: Among the 436 study participants, 283 (64.9%) had no cervical intraepithelial neoplasia (CIN), while 53 (12.2%) had CIN1, 40 (9.2%) had CIN2, 34 (7.8%) had CIN3, and 26 (5.9%) had cervical cancers. The CISCER tests identified all cases of cervical cancer, particularly 2 hrHPV-negative adenocarcinoma cases. In 396 hrHPV+ individuals, the sensitivity of CISCER tests for detecting CIN2+ lesions was 92.6% (95% CI: 87.2-97.9%), with a specificity of 95.7% (95% CI: 93.4-98%), and an area under the receiver operating characteristic curve (AUC) of 0.941 (95% CI: 0.903-0.979), outperforming cytology tests in both HPV16/18+ and non-16/18 hrHPV+ women. Notably, CISCER demonstrated 100% (95% CI: 90-100%) sensitivity in women aged≥50 and 100% (95%CI: 93.6-100%) specificity in women aged<30. Among CIN2+ women, 37.2% (including 3 cancer) showed low-grade cytological changes that could be detected by CISCER. Meanwhile, 52% of CIN2- women exhibited cytological abnormalities but had negative CISCER results. The immediate CIN3+ risk based on positive CISCER results was 54% (95% CI: 43.8-63.9%). Conclusion: The

Indexed as

cervical cancerhigh-risk HPV positivejunctional adhesion molecule 3paired box gene 1PAX1/JAM3 methylation

Identifiers

PMID39659794
PMCPMC11628385

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.